Abstract | Keywords | Export | Availability | Bookmark

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

As the infections caused by multidrug-resistant Gram-positive bacteria remain a worldwide issue in tenus of morbidity and mortality but also in terms of increased expenditure on patient management, important research in the field led to the introduction of a large number of novel antibacterial agents. Among the new antibiotics being developed against meticillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, oritavancin a new lipoglycopeptide seems able to circumvent high level of glycopeptides resistance. The story behind this agent reveals the pharmaceutical business and regulatory challenge that can have a major impact on development of new antibiotics (Norris E. allen et coll, 2010). As the development of this agent started in 1985 and has not yet receives any approval, the aim of this paper is to determine whether or not there is a future for oritavancin

oritavancin --- telavancin --- Anti-Bacterial Agents --- Vancomycin